Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of SpectrumX.

    Client Virtual Booth

    SPECTRUMX

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    SpectrumX
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Unit 8 Novus, Parkgate Industrial Estate, Haig Road, Knutsford, WA16 8FB
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://spectrumx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/spectrum-x/
    Twitter
    Twitter
    https://twitter.com/spectrumx_ofc

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SpectrumX Confirms Next Step in Clinical Development of Respiratory Drug Candidate SPX-001 After MHRA Meeting

    Details:

    SPX-001 is SpectrumX’s nebulised respiratory infection drug candidate, based on the Company’s licensed hypochlorous acid (HOCl)-based SPC-069 drug substance, which is believed to have broad-spectrum antipathogenic properties.


    Lead Product(s): Hypochlorous Acid Based SPX-069

    Therapeutic Area: Infections and Infectious Diseases Product Name: SPX-001

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 24, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SpectrumX Reaches Partnership Agreement on Human Volunteer Study for Ground-breaking Respiratory Infection Drug Candidate SPX-001

    Details:

    Start-up agreement is major step forward in readiness to conduct Phase 1b clinical trial of Company’s HOCl-based respiratory infection drug candidate, SPX-001.


    Lead Product(s): SPX-001

    Therapeutic Area: Infections and Infectious Diseases Product Name: SPX-001

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Undisclosed

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership September 20, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SpectrumX Confirms Scientific Advice Meeting With MHRA, Proposed Timeline for Human Clinical Trials for Ground-Breaking Medicine SPX-001

    Details:

    SpectrumX has confirmed scientific advice meeting with MHRA and will discuss the available data supporting the commencement of human trials with SPX-001 (Hypochlorous Acid) protocol for Phase Ib human volunteer study, prior to submission of CTA submission.


    Lead Product(s): Hypochlorous Acid

    Therapeutic Area: Infections and Infectious Diseases Product Name: SPX-001

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 08, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    SpectrumX Partners With Leading UK Specials Group to Accelerate Production of Anti-Pathogenic Drug for Clinical Trials

    Details:

    SPX-001 is a potential novel treatment, based on hypochlorous acid (HOCl), for respiratory infections and is a new drug candidate for Europe with broad-spectrum anti-pathogenic properties.


    Lead Product(s): Hypochlorous Acid

    Therapeutic Area: Infections and Infectious Diseases Product Name: SPX-001

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Undisclosed

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership August 03, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search